Overview

Study of ADI-PEG 20 Versus Placebo in Subjects With Genotype WWOX-GG, Unresectable HCC

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Evaluate efficacy and safety of ADI-PEG 20 in patients with genotype WWOX-GG and HCC
Phase:
Phase 3
Details
Lead Sponsor:
Polaris Group